Loading
A phase 2 trial of Rituximab, Bortezomib and Ibritumomab tiuxetan in Mantle cell lymphoma, run by Duke University, recorded as terminated on the registry.
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT01497275 by Duke University, with 5 participants recorded, started 2012-02 and due to reach its primary completion in 2014-05. Interventions recorded: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan. Conditions recorded: Mantle-Cell Lymphoma.
Linked to the drug Ibritumomab tiuxetan because the registry names it among its interventions and Mantle cell lymphoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
5 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2015-06-04), not from a publication
SourceFigures from the ClinicalTrials.gov results section (first posted 2015-06-04), not from a publication
SourceFigures from the ClinicalTrials.gov results section (first posted 2015-06-04), not from a publication
SourceShares Ibritumomab tiuxetan, Rituximab and the tag pipeline.
Shares Ibritumomab tiuxetan and the tag pipeline.
Shares Rituximab, Mantle cell lymphoma and the tag pipeline.
Shares Mantle cell lymphoma and the tag pipeline.
Shares Rituximab, Mantle cell lymphoma and the tag pipeline.
Shares Rituximab and the tag pipeline.
Shares Rituximab and the tag pipeline.
Shares Rituximab and the tag pipeline.